We round up the latest deals and partnership news from across the Health Tech World.
Angelini Ventures leads €10 million Series A financing in Vantis, a Digital Care Innovation company
Angelini Ventures has led a €10 million Series A financing round in Vantis Health, a company aiming to transform primary care through the integration of digital therapies and innovative care models.
The financing will enable Vantis to continue developing its data-driven, proactive approach to chronic disease management, as well as to expand its team and enhance its use of telemedicine, continuous monitoring, digital therapies and AI-powered processes.
Till Jansen, Co-founder and CEO of Vantis, said: “Significant investments are essential for the digital transformation of the healthcare system so that in the end, everyone benefits: doctors, patients, and payers.
“As a software company with our own practices, we have the unique ability to tailor our technology to the current challenges in primary care and continuously optimise it.
“Our goal is to achieve better treatment outcomes for patients while simplifying doctors’ daily routines—so they can focus more on what truly matters: providing medical care.”
StimOxyGen secures £1.5m to advance breakthrough therapy overcoming cancer treatment resistance
StimOxyGen, a spin-out from Ulster University, has raised £1.5m, led by DSW Ventures, to accelerate the development of its therapy designed to overcome treatment resistance in solid tumours.
By delivering oxygen directly to tumours, the company’s lead candidate aims to enhance the effectiveness of treatments such as radiotherapy and immunotherapy, offering a potential lifeline for patients with aggressive cancers.
StimOxyGen will initially focus on pancreatic cancer, a disease with a five-year survival rate of just 13 per cent and limited treatment options.
The funding will allow StimOxyGen to advance key preclinical studies, scale-up manufacturing and expand its team as it moves towards clinical translation.
Sian Farrell, CEO of StimOxyGen, said: “Hypoxia is one of the biggest barriers to effective cancer treatment.
“Our technology has the potential to transform how solid tumours are treated by making them more vulnerable to standard therapies.
“This funding allows us to accelerate preclinical development and take key steps towards clinical trials.”
Synvect secures $3m seed round to combat mosquito-borne diseases with CRISPR tech
Synvect, Inc., a biotechnology startup developing next-generation vector control solutions, has raised a $3m Seed Round.
The funding will accelerate the development and deployment of Synvect’s CRISPR-based technology, offering a scalable, eco-friendly solution to suppress disease-carrying mosquito populations.
The company uses CRISPR to produce sterile male mosquitoes, which, when released, mate with wild females—who only mate once—preventing reproduction.
Dr. Nikolay Kandul, CEO of Synvect, said: “This technology has the potential to eliminate mosquito-borne diseases in large regions.
“We are thrilled to have the support of leading investors and regulators as we move towards large-scale implementation.”
TeleTracking Technologies and Faculty announce strategic partnership
TeleTracking Technologies, a developer of healthcare operations and patient flow technology, has entered a 5-year, multimillion dollar partnership with applied AI company, Faculty.
The partnership will equip hospitals and health systems with AI-enabled automation and predictive capabilities that enable smarter, data-driven operational decisions.
Faculty’s novel simulation technology will be embedded into TeleTracking’s healthcare operations and data platform, Operations IQ.
This will provide hospitals and health systems with robust operational scenario planning capabilities, powered by AI.
The integration aims to enhance the predictive and prescriptive capabilities of TeleTracking’s platform, redefining how health systems approach capacity management, patient flow and resource optimisation in an era of increased demand and complexity.
Chris Johnson, TeleTracking’s Co-CEO, said: “We’re excited to partner with Faculty as we continue to define what’s possible in healthcare operations.
“Together, we’re committed to enhancing our healthcare operations and data platform with Faculty’s impactful AI solutions to enable operational agility and responsiveness for hospitals and health systems across the globe.”
Elsevier launches ScienceDirect AI in effort to transform research
Global information analytics company Elsevier has launched ScienceDirect AI, a generative AI tool for researchers.
It is designed to transform the way researchers work by enabling them to instantly extract, summarise and compare trusted insights from millions of full-text articles and book chapters on ScienceDirect, the world’s largest platform for peer-reviewed research.
Studies show that researchers spend 25 per cent-35 per cent of their time sifting through literature.
ScienceDirect AI helps address this challenge by drawing on the broadest and deepest content set of millions of peer-reviewed full-text research articles and book chapters to generate instant accurate summaries and highlight key findings, while providing references to support the reproducibility and integrity of research.
Judy Verses, Elsevier President of Academic and Government Markets, said: “Feedback from users worldwide suggests ScienceDirect AI could be a game changer for researchers who are grappling with information overload and want to get accurate insights they can rely on, fast.
“ScienceDirect is the platform of choice globally for millions of researchers, so this new generative AI tool will seamlessly integrate into their current ways of working, enabling them to dedicate more time to research and achieve results.”
